Monopar Therapeutics (MNPR) Non-Current Debt (2020)
Monopar Therapeutics (MNPR) posted Non-Current Debt of $54628.0 for Q3 2020, down 27.18% sequentially from $75021.0 in Q2 2020.
Powered by 
Analysis
Monopar Therapeutics (MNPR) Non-Current Debt (2020) Analysis & Trends
Monopar Therapeutics has reported Non-Current Debt for 1 years, with the latest figure at $54628.0 in Q3 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.87 Bn | 131.01 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.57 Bn | 77.57 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.19 Bn | 53.05 Bn | 52.00 Mn | 591.00 Mn |
| 5 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 882.16 Mn |
| 7 | Alnylam Pharmaceuticals | 35.38 Bn | 32.07 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 8.96 Bn |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Monopar Therapeutics | 1.01 Bn | 956.53 Mn | - | - |